Similar Articles

Browse Main Topics:

Business
Computers & Electronics
Education & Reference
Entertainment & Leisure
Family & Home
Finance & Investment
Health
Internet
Pets & Animals
Science & Technology
Society, Politics & Culture
Sports & Recreation

Similar Articles

The Motley Fool January 24, 2010 Jeff Fischer	4 Reasons to Sell a Stock Sell decisions are difficult, but these guidelines can help.
The Motley Fool June 18, 2009 Jeff Fischer	4 Reasons to Sell a Stock When to jettison a stock is a difficult decision, however, these guidelines can make selling decisions easier.
The Motley Fool August 24, 2010 Matt Koppenheffer	How Much Is Johnson & Johnson Worth? Is Johnson & Johnson's stock on sale?
The Motley Fool September 17, 2010 Morgan Housel	5 Companies That Doubled Earnings While Their Stocks Went Nowhere When being "paid for performance" loses its mind.
The Motley Fool October 26, 2011	A Brief History of Johnson & Johnson's Returns J&J shares are much more reasonably valued today than they were ten years ago; shareholders are unlikely to experience the same going forward.
The Motley Fool October 12, 2007 Ryan Fuhrmann	Dueling Fools: Johnson & Johnson Bull The bullish opinion on J&J is that the company is handling current difficulties well, and the low stock price makes for a bargain for investors.
The Motley Fool January 13, 2012 Morgan Housel	5 Companies You Can Buy Today Cheap by the numbers.
The Motley Fool March 24, 2011 Anand Chokkavelu	Rising Star Buy: Johnson & Johnson It's time to buy shares of Johnson & Johnson, the "health-care mutual fund."
The Motley Fool December 21, 2006 Ryan Fuhrmann	Dueling Fools: Merck Bear Investors, because of its recent run-up, the risk/reward tradeoff is not very compelling. There are safer, more lucrative ways to invest in the space.
The Motley Fool September 27, 2005 Marko Djuranovic	Knowing When to Sell: Part 2 If you'd no longer want to buy that stock sitting in your portfolio, it's time to cut it loose. Just make sure you're getting your fair value.
The Motley Fool September 17, 2010 James Early	Today's Buy Opportunity: Johnson & Johnson The case for Johnson & Johnson is very simple: Here's a company that's been around forever, that pays a 3.5% dividend, and that's spread across arguably the most necessary sector (behind water and sewage): health care.
The Motley Fool November 22, 2006 Steven Mallas	Dueling Fools: Johnson & Johnson Bull Rebuttal Plenty of opportunities lie ahead for Johnson & Johnson, and even in down times, you've got a good defensive stock.
The Motley Fool September 24, 2010 Anand Chokkavelu	10 Core Stocks for Your Portfolio: Johnson & Johnson The health care behemoth makes the list
The Motley Fool October 27, 2009 Brian Orelli	Pfizer's and Merck's Loss Is These Companies' Gain Are Pfizer and Merck too busy integrating now to take advantage of additional acquisitions?
The Motley Fool October 25, 2010 Morgan Housel	5 Companies You Can Buy Today These are cheap by the numbers: Johnson & Johnson... Kraft Foods... IBM... Costco... Wal-Mart...
The Motley Fool November 29, 2007 Anders Bylund	Mano a Mano Over Johnson & Johnson A look back at the past year at Johnson & Johnson.
BusinessWeek January 30, 2006 Robert Barker	Guidant Or No, J&J Is A Buy To Wall Street, Johnson & Johnson has been sounding like Dumb & Dumber.
The Motley Fool September 27, 2010 Brian Orelli	This Recall Is Different -- In a Good Way Johnson & Johnson strikes again, but it's not so bad this time.
The Motley Fool October 22, 2010 Anand Chokkavelu	7 Big Pharma Stocks Near 52-Week Lows Trolling the bottom for upside potential.
The Motley Fool October 30, 2007 Philip Durell	World's Scariest Stock: Research In Motion Great product, great company, but valuation has become too high. Investors, take note.
The Motley Fool December 18, 2008 Selena Maranjian	Best Stock for 2009: Johnson & Johnson Johnson & Johnson is a stock that should let you sleep well at night in 2009.
The Motley Fool June 30, 2009 Brian Orelli	Johnson & Johnson Inflames Abbott $1.67 billion is one hefty reward.
The Motley Fool January 28, 2011 Anand Chokkavelu	10 Core Stocks: A Johnson & Johnson Update The steady reliability of J&J stock will comfort the core of your portfolio when the market gets a boo-boo.
The Motley Fool December 31, 2008 Dan Caplinger	And the Best Stock for 2009 Is ... Find out which stock you picked to rule the roost in 2009.
The Motley Fool November 22, 2006 Brian Lawler	Dueling Fools: Johnson & Johnson Bear Rebuttal The bottom line is that investors are putting their faith in the ability of J&J's management to acquire its way to renewing top-line growth in the coming years.
The Motley Fool April 20, 2005 Jeff Hwang	From Poker to Investing: Always Look Ahead Focus on valuation, always look ahead, and keep it simple. A look at three suggestions about investing using poker theoretician Mike Caro's tips.
The Motley Fool July 26, 2010 Dan Dzombak	Defend Yourself From the Double Dip With These 5 Stocks 5 cheap mega cap stocks to protect your portfolio
The Motley Fool June 2, 2005 Matt Thurmond	Quality Systems or Not? Quality Systems' growth prospects were trading at a discount back in 2003. Those days are gone. But does that mean you shouldn't buy?
The Motley Fool September 28, 2009 Brian Orelli	The Berkshire of Health Care Johnson & Johnson is becoming the Berkshire Hathaway of health care. In addition to its usual M.O. of bolt-on acquisitions, the health-care giant has recently taken some equity stakes in smaller drug companies.
The Motley Fool December 31, 2007 Brian Orelli	Best Stock for 2008: Johnson & Johnson Down on its luck for 2007, here's why Johnson & Johnson's stock will rebound in 2008.
The Motley Fool May 31, 2007 Ryan Fuhrmann	Dueling Fools: Eli Lilly Bull Rebuttal Investors need to keep looking for further proof that Lilly's valuation premium to its peers is fully warranted, but if current trends are any indication, its growth prognosis could lead the industry.
The Motley Fool August 19, 2010 Brian Orelli	Buffett Is Buying J&J. Should You? It depends on your time horizon.
The Motley Fool March 11, 2011 Brian Orelli	Johnson & Johnson Gets a Slap on the Wrist The consent decree could have been a lot worse.
The Motley Fool December 21, 2006 Ryan Fuhrmann	Dueling Fools: Merck Bear Rebuttal Yes, Merck is a good company, but investors can still do better.
BusinessWeek December 22, 2003 Robert Barker	A Stimulant For Depressed Drug Stocks? For a bunch of can't-miss stocks, the big drugmakers sure did miss out on 2003's bull run. The dozen drug companies in the Standard & Poor's 500-stock index have returned 10% this year, vs. the index' 22%. But the market is now failing to credit the companies' strengths.
The Motley Fool July 12, 2011 Todd Wenning	What Does Johnson & Johnson Do With Its Free Cash? Johnson & Johnson appears to be making fair use of its free cash flow, and its well-covered dividend may be attractive to income-focused investors.
The Motley Fool August 11, 2010 David Meier	Does Bill Miller Think Johnson & Johnson Is Attractive? Johnson & Johnson fits Miller's criteria perfectly. It pays a 3.6% dividend that has been growing 11.1%, on average, for the past five years.
The Motley Fool May 27, 2011 Morgan Housel	2 Huge Lessons From Microsoft and IBM That Every Investor Should Know Valuation determines everything; what a company does with its cash is vital.
The Motley Fool September 29, 2011 Brian Orelli	Joint-Venture Acid Reflux Merck ditches its joint venture with Johnson & Johnson.
The Motley Fool September 30, 2009 Brian Orelli	Bigger Size, Lower Returns History is not on Merck and Schering's side.
The Motley Fool July 16, 2008 Brian Orelli	J&J's Lesson to Investors: Diversify! Johnson & Johnson's second-quarter earnings report gives investors an object lesson of the benefits of the principle of diversification.
The Motley Fool November 7, 2005 Stephen D. Simpson	All's Not Lost at Guidant Eroding sales, a partner with cold feet, and all sorts of litigation and investigation cloud Guidant's skies. Investors, take note.
The Motley Fool February 10, 2006 Stephen D. Simpson	UTStarcom Still a Mess A contract revenue recognition problem serves as a reminder of the management quality issues here. Valuation is enticingly low, and simply a mediocre performance from management should be enough to make this company profitable.
The Motley Fool September 25, 2009 Brian Orelli	Oh, No! Another Tylenol Recall? Take a deep breath. Everything will be OK.
The Motley Fool October 19, 2010 Brian Orelli	Watch a 40% Decline Disappear The greatest thing going for Johnson & Johnson is its diversity in product offerings.
The Motley Fool June 26, 2006 Stephen D. Simpson	J&J Makes an Expensive Deal J&J announced that it has reached an agreement with Pfizer to acquire the latter's consumer health-care business for $16.6 billion in cash. Consumer health is a fine business line, but is it worth this much money? Investors, take note.
The Motley Fool December 22, 2010 Stephen J. Marini	Are These High-Yield Stocks Too Good to Be True? Look deep into the numbers on high yielders to avoid dividend traps.
The Motley Fool August 18, 2010 Tim Hanson	Don't Buy This Stock ... Yet Promising names that aren't quite buys.
The Motley Fool June 10, 2006 Rex Moore	The Best Stocks for New Money It's time to add new money. What will you do? The most important consideration, especially for the average individual investor, is balance: between large and small caps, between less risk and more risk, and among different industries.
The Motley Fool October 26, 2009 Adam J. Wiederman	Time to Sell and Lock in Your Gains With stocks up so much, it might be time to take some money off the table.